UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

May 31, 2006

Conditions

Adenocarcinoma of the PancreasRecurrent Pancreatic CancerStage II Pancreatic CancerStage III Pancreatic CancerStage IV Pancreatic Cancer

Interventions

DRUG

7-hydroxystaurosporine

Given IV

DRUG

gemcitabine hydrochloride

Given IV

OTHER

pharmacological study

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

M D Anderson Cancer Center, Houston

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00039403 - UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter